Benefits
Traditional use for eye irritation (eye drop study only)
Eyebright has been used for centuries as both an oral supplement and topical eye wash for conjunctivitis, eye redness, and irritation. The only clinical study used sterile single-dose eyebright eye drops, not a supplement you swallow. It followed 65 people with conjunctivitis for up to 14 days and reported that redness, discharge, and itching improved. It was an uncontrolled cohort study with no placebo group and no blinding, and conjunctivitis usually clears on its own within about a week, so the improvement cannot be credited to the drops. There was no comparison with conventional treatment. Nothing in this study tells you what taking eyebright by mouth does for your eyes.
Dry eye: laboratory rationale only
Eyebright's tannins and flavonoids (luteolin, quercetin) show astringent and anti-inflammatory activity in laboratory tests, and that is the usual rationale offered for dry eye. It is laboratory reasoning only. No study cited on this page tested eyebright in people with dry eye, by mouth or in the eye, and none measured tear film stability or ocular surface inflammation. Traditional use for 'weary, tired eyes' aligns with modern understanding of evaporative dry eye driven by lid margin inflammation.
Seasonal eye allergy: proposed mechanism only
Quercetin and luteolin can stabilize mast cells and reduce histamine release in laboratory studies, which is the proposed rationale for allergic eye symptoms. That rationale has never been tested for eyebright in people. The reference cited here is a narrative review of complementary and alternative approaches to eye allergy, not a trial of eyebright, and it describes the evidence as limited and mixed. Saying eyebright addresses the allergic component of eye irritation, or comparing it with antihistamine eye drops, goes well beyond anything that has been measured.
Upper respiratory mucosal support
Beyond eye health, eyebright has a long tradition in European herbal medicine for upper respiratory tract conditions — sinusitis, rhinitis, nasal congestion, and hay fever. This use rests on tradition alone. No study cited on this page looked at sinus, nasal, or hay fever symptoms, so there is no human evidence that eyebright reduces mucus, congestion, or nasal inflammation.
Mechanism of action
Aucubin iridoid anti-inflammatory activity
Aucubin — eyebright's primary iridoid glycoside — reduces inflammatory signalling such as NF-κB activity and COX-2 in isolated cells and in animal studies. These are laboratory findings, not measurements made in anyone's eyes or airways. Aucubin is hydrolyzed by gut bacteria to aucubigenin, which has demonstrated hepatoprotective and anti-inflammatory activity in cell and animal studies.
Flavonoid mast cell stabilization and antihistamine activity
In laboratory studies, the flavonoids luteolin and quercetin can block mast cells from releasing histamine and inflammatory signals. This work uses isolated cells and purified flavonoids, not eyebright taken by people, so it describes a proposed mechanism rather than a proven effect. These flavonoids also inhibit 5-lipoxygenase, reducing leukotriene production that drives the vascular permeability and tissue swelling of allergic eye and nasal conditions.
Tannin astringency and vascular permeability reduction
Eyebright's condensed tannins precipitate surface proteins on conjunctival epithelium and mucous membranes, which is the traditional explanation for why an eyebright wash was thought to reduce weeping and discharge. This is a proposed mechanism only. Eyebright has not been shown to limit bacterial growth, prevent infection, or shorten conjunctivitis in any controlled study.
Clinical trials
Prospective cohort study with no control group, no placebo, and no blinding, using sterile single-dose eyebright eye drops in 65 people with conjunctivitis (catarrhal, allergic, mixed) followed for up to 14 days. The product was dripped into the eye, so the results say nothing about eyebright capsules, tincture, or tea. (Stoss et al. 2000, J Altern Complement Med)
65 people with conjunctivitis. 14 days, uncontrolled cohort, no placebo. Eye drops, not an oral supplement.
Redness, discharge, foreign body sensation, and itching improved over the follow-up in the people taking part. Critical caveat: with no control group, no placebo, and no comparison treatment, improvement over time cannot be attributed to the drops. Cannot establish efficacy vs natural resolution or placebo effect. Conjunctivitis (especially viral) often resolves spontaneously in 5-7 days. Modern ophthalmology does not recommend eyebright in clinical guidelines.
A general reference to cell culture and animal work on aucubin, an iridoid glycoside found in eyebright and in other plants such as plantain. No specific published study is cited for this entry, and none of this work involved people or eyebright itself.
In vitro and animal models (not clinical trials).
Aucubin reduced NF-κB activation, COX-2 expression, and PGE2 production in LPS-stimulated macrophages. Critical caveat: this is bench research only. Translation to clinical efficacy in human conjunctivitis or other indications has not been demonstrated. Many plant-derived compounds show anti-inflammatory activity in vitro without clinical relevance.